Pharmaceutical company

On October 24th, 2016 Inovio Pharmaceuticals (INO) announced the FDA had placed a hold on its proposed Phase 3 trial for its electroporation system CELLECTRA, being tested in combintion with immunotherapy treatment VGX-3100, over concerns about the product’s shelf life. Generally speaking, this delay has sparked greater investor interest in electroporation immunotherapy and the pharmaceutical companies (NASDAQ:INO, NYSE:PFE, VTX:ROG, and private company Ichor) working to advance the technology. This

chosen to do our financial analysis is Health Care. The Health Care market sector is then further divided into six main sub-sectors, for which our three companies, Johnson & Johnson (JNJ), Pfizer (PFE), and AstraZeneca (AZN), are categorized in the Pharmaceutical sub-sector. Furthermore, Yahoo Finance’s industry center labels these three companies as being Drug Manufacturers-Major. This industry is unique in that it has both defensive and cyclical aspects due to the overall need for medical treatment

circle that starts with the lack of diagnosis of Chagas disease. Without diagnosis, the governments are not requested for Chagas treatment, and therefore the governments do not request treatment medications from pharmaceutical companies, without demand for Chagas treatment, these companies will not spend their resources in the research and development of more efficient medications or treatment. MSF is assisting Mexico in diagnosing the people with Chagas Disease and providing treatment to the people

Social Responsibility (CSR) Consumers all over the world are pressuring companies to become more socially responsible. Corporate Social Responsibility (CSR) is a measurement of a business’ impacts on society, both positive and negative. Pharmaceutical companies in particular are held to a high ethical standard by the public due to the nature of their product. Novartis, one of the largest healthcare and pharmaceutical companies in the world, aspires to be a model of ethics and philanthropy in the industry

advertising, as one of the most effective forms of mass communications, should be more regulated than it is now. This debate does not seem to go end. I, however, argue that people need stronger regulations against many DTC advertisements in a pharmaceutical industry because they are usually manipulative and misleading to people. Many proponents of DTC advertising emphasize that it let consumers make educated decisions, and regulations against advertising are a violation of freedom of speech. Furthermore

Ever since the legalization of direct-to-consumer pharmaceutical advertising in 1985, drug companies have grown and greatly increased their spending, making this the most popular type of health communication to the general public. From 1996 to 2005, the total amount of spending on pharmaceutical advertisements increased by 3252 million dollars and the percentage of drug sales increased by 1.4 percent (New England Journal of Medicine). This positive increase in sales is why the United States allows

On September 2nd 2011, a Twenty-four year old man from Cincinnati named Kyle Willis´ fell victim to the corruption of the pharmaceutical industry(Gann, Carrie). Willis had a severe toothache on his wisdom tooth that resulted in its extraction. After the surgery, Willis´s face started to swell and was sent to the emergency room. He was prescribed antibiotic medications and also painkillers in order to follow standard recovery procedure. Kyle Willis’ could not afford both drugs so he just purchased

vaccination. Here’s how they are doing it: The pharmaceutical companies that develop and produce the recommended vaccinations and medications, donate millions of dollars to the FDA. In 2014 their donations made up 94% of the FDA’s total budget, which ended up equaling 4.7 billion dollars (Mercola). The FDA is the Food and Drug Administration, which is an agency within the U.S. Department of Health and Human Services. Once the FDA approves the pharmaceutical companies new medications or vaccinations, their

relationships and is that involvement actually costing employees more. The article I chose is entitled “Government Mandates Don’t Lower Healthcare Costs” (Forbes 2013). The main focus discusses the impact that government has had on the rise in pharmaceutical costs through the 340b program implemented by President George W. Bush and congress back in 1992 (Forbes 2013). The

middle-market pharmaceutical and biotechnology corporate growth. While multinationals fill their innovation pipelines in North America, branded and generic producers alike are expanding their real estate footprints to reach new markets in Asia and South America, according to JLL’s fourth annual Life Sciences Outlook Report . “The challenge to stay nimble and respond to sales and manufacturing opportunities is shaping life sciences